Compounds > chidamide
Page last updated: 2024-11-12

chidamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID12136798
CHEMBL ID3621988
CHEBI ID135918
SCHEMBL ID13815849

Synonyms (45)

Synonym
CHEBI:135918
tucidinostat [usan]
benzamide, n-(2-amino-4-fluorophenyl)-4-((((2e)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)-
cs-055
benzamide, n-(2-amino-4-fluorophenyl)-4-(((1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)-
tucidinostat [who-dd]
tucidinostat [inn]
chidamide [who-dd]
tucidinostat
743438-44-0
hbi-8000
tucidinostat [jan]
n-(2-amino-4-fluorophenyl)-4-(((2e)-3-(pyridin-3-yl)prop- 2-enamido)methyl)benzamide
87CIC980Y0 ,
epidaza
n-(2-amino-4-fluorophenyl)-4-(((1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)benzamide
SCHEMBL13815849
CHEMBL3621988
de-5-fluoro 4-fluorochidamide
AKOS027323972
n-(2-amino-4-fluorophenyl)-4-{(3-(pyridin-3-yl)prop-2-enamido)methyl}benzamide n-(2-amino-4-fluorophenyl)-4-{((2e)-3-(pyridin-3-yl)prop-2-enamido)methyl}benzamide
benzamide, n-(2-amino-4-fluorophenyl)-4-(((1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)-benzamide, n-(2-amino-4-fluorophenyl)-4-((((2e)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl)amino)methyl)-
1616493-44-7
unii-87cic980y0
tucidinostat (jan/usan/inn)
D10993
epidaza (tn)
(e)-n-(2-amino-4-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide
HY-109015
CS-0030513
cs 055
DB06334
BS-15501
Q19903814
chidamide; hbi-8000; cs-055 hcl
tucidinostat hcl
A51185
n-(2-amino-4-fluorophenyl)-4-[[[(e)-3-pyridin-3-ylprop-2-enoyl]amino]methyl]benzamide
EX-A3245
epidaza in china
bdbm50457079
A899933
n-(2-amino-4-fluorophenyl)-4-((3-(pyridin-3-yl)acrylamido)methyl)benzamide
n-(2-amino-4-fluorophenyl)-4-{[(2e)-3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
DTXSID701032295

Research Excerpts

Overview

Chidamide is a histone deacetylase (HDAC) inhibitor that is currently used to treat cutaneous T-cell lymphoma in clinic.

ExcerptReferenceRelevance
"Chidamide is a histone deacetylase (HDAC) inhibitor that is currently used to treat cutaneous T-cell lymphoma in clinic. "( Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
Chen, S; Dong, G; Huang, Y; Sheng, C; Wang, L; Wu, S; Wu, Y, 2020)		2.23

Toxicity

ExcerptReferenceRelevance
" Treatment was well tolerated; adverse events were predominantly mild to moderate hematologic toxicities and were managed with dose modification and supportive care."( Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy.
Ando, K; Choi, I; Gillings, M; Hidaka, M; Ishida, T; Lee, GT; Onogi, H; Takamatsu, Y; Tobinai, K; Yoshida, S; Yoshimitsu, M, 2022)		0.72

Bioavailability

ExcerptReferenceRelevance
" HBI-8000 is a novel, orally bioavailable class I selective histone deacetylase inhibitor that directly modifies antitumor activity by inducing apoptosis, cell cycle arrest, and resensitization to apoptotic stimuli in adult T cell lymphoma patients."( The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Bissonnette, RP; Cesario, RM; Gillings, M; Goodenow, B; Shojaei, F, 2021)		0.62

Dosage Studied

ExcerptRelevanceReference
" The maximum tolerated dose and recommended dosage for phase II studies of HBI-8000 is 40 mg BIW."( Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy.
Ando, K; Choi, I; Gillings, M; Hidaka, M; Ishida, T; Lee, GT; Onogi, H; Takamatsu, Y; Tobinai, K; Yoshida, S; Yoshimitsu, M, 2022)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone deacetylase 3Homo sapiens (human)IC50 (µMol)1.61240.00040.619610.0000AID1340801; AID1541810; AID1589338; AID1740042; AID1915571
AcetylcholinesteraseMus musculus (house mouse)IC50 (µMol)0.16700.00071.11818.4000AID1594026
Nicotinamide phosphoribosyltransferaseHomo sapiens (human)IC50 (µMol)2.10000.00010.07102.1000AID1541807
Histone deacetylase 4Homo sapiens (human)IC50 (µMol)5.78900.00061.052610.0000AID1340801; AID1740131; AID1915571
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)0.87600.00010.55439.9000AID1340801; AID1379287; AID1541808; AID1589336; AID1594026; AID1740040; AID1825073; AID1884268; AID1899789; AID1915571
Histone deacetylase 7Homo sapiens (human)IC50 (µMol)5.78900.00071.02609.9000AID1340801; AID1740115; AID1915571
Histone deacetylase 2Homo sapiens (human)IC50 (µMol)1.62540.00010.72219.9700AID1340801; AID1541809; AID1589337; AID1740041; AID1915571
Polyamine deacetylase HDAC10Homo sapiens (human)IC50 (µMol)1.92550.00050.72459.9000AID1340801; AID1589345; AID1739999; AID1915571
Histone deacetylase 11 Homo sapiens (human)IC50 (µMol)2.13170.00030.92989.9000AID1340801; AID1589346; AID1740134; AID1915571
Histone deacetylase 8Homo sapiens (human)IC50 (µMol)2.22500.00070.99479.9000AID1340801; AID1589339; AID1740116; AID1915571
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)5.78900.00000.53769.9000AID1340801; AID1740114; AID1915571
Histone deacetylase 9Homo sapiens (human)IC50 (µMol)5.78900.00050.94139.9000AID1340801; AID1740117; AID1915571
Histone deacetylase 5Homo sapiens (human)IC50 (µMol)5.78900.00070.961010.0000AID1340801; AID1740113; AID1915571
Nuclear receptor corepressor 2Homo sapiens (human)IC50 (µMol)0.33000.00170.59528.0000AID1541810
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (198)

Processvia Protein(s)Taxonomy
negative regulation of myotube differentiationHistone deacetylase 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
establishment of mitotic spindle orientationHistone deacetylase 3Homo sapiens (human)
in utero embryonic developmentHistone deacetylase 3Homo sapiens (human)
positive regulation of protein phosphorylationHistone deacetylase 3Homo sapiens (human)
chromatin organizationHistone deacetylase 3Homo sapiens (human)
transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
protein deacetylationHistone deacetylase 3Homo sapiens (human)
regulation of mitotic cell cycleHistone deacetylase 3Homo sapiens (human)
positive regulation of protein ubiquitinationHistone deacetylase 3Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 3Homo sapiens (human)
positive regulation of TOR signalingHistone deacetylase 3Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
regulation of multicellular organism growthHistone deacetylase 3Homo sapiens (human)
positive regulation of protein import into nucleusHistone deacetylase 3Homo sapiens (human)
regulation of circadian rhythmHistone deacetylase 3Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 3Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 3Homo sapiens (human)
negative regulation of JNK cascadeHistone deacetylase 3Homo sapiens (human)
spindle assemblyHistone deacetylase 3Homo sapiens (human)
establishment of skin barrierHistone deacetylase 3Homo sapiens (human)
cellular response to fluid shear stressHistone deacetylase 3Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone deacetylase 3Homo sapiens (human)
DNA repair-dependent chromatin remodelingHistone deacetylase 3Homo sapiens (human)
cornified envelope assemblyHistone deacetylase 3Homo sapiens (human)
negative regulation of cardiac muscle cell differentiationHistone deacetylase 3Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 3Homo sapiens (human)
insulin receptor signaling pathwayNicotinamide phosphoribosyltransferaseHomo sapiens (human)
adipose tissue developmentNicotinamide phosphoribosyltransferaseHomo sapiens (human)
signal transductionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
cell-cell signalingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of cell population proliferationNicotinamide phosphoribosyltransferaseHomo sapiens (human)
circadian regulation of gene expressionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processNicotinamide phosphoribosyltransferaseHomo sapiens (human)
NAD biosynthetic processNicotinamide phosphoribosyltransferaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
chromatin remodelingHistone deacetylase 4Homo sapiens (human)
protein deacetylationHistone deacetylase 4Homo sapiens (human)
inflammatory responseHistone deacetylase 4Homo sapiens (human)
nervous system developmentHistone deacetylase 4Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 4Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 4Homo sapiens (human)
response to denervation involved in regulation of muscle adaptationHistone deacetylase 4Homo sapiens (human)
cardiac muscle hypertrophy in response to stressHistone deacetylase 4Homo sapiens (human)
protein sumoylationHistone deacetylase 4Homo sapiens (human)
B cell differentiationHistone deacetylase 4Homo sapiens (human)
positive regulation of protein sumoylationHistone deacetylase 4Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 4Homo sapiens (human)
B cell activationHistone deacetylase 4Homo sapiens (human)
regulation of protein bindingHistone deacetylase 4Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 4Homo sapiens (human)
negative regulation of glycolytic processHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 4Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 4Homo sapiens (human)
type I interferon-mediated signaling pathwayHistone deacetylase 4Homo sapiens (human)
response to interleukin-1Histone deacetylase 4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 7Homo sapiens (human)
vasculogenesisHistone deacetylase 7Homo sapiens (human)
chromatin remodelingHistone deacetylase 7Homo sapiens (human)
protein deacetylationHistone deacetylase 7Homo sapiens (human)
cell-cell junction assemblyHistone deacetylase 7Homo sapiens (human)
protein sumoylationHistone deacetylase 7Homo sapiens (human)
negative regulation of interleukin-2 productionHistone deacetylase 7Homo sapiens (human)
negative regulation of osteoblast differentiationHistone deacetylase 7Homo sapiens (human)
regulation of mRNA processingHistone deacetylase 7Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 7Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionHistone deacetylase 7Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
response to amphetamineHistone deacetylase 2Homo sapiens (human)
cardiac muscle hypertrophyHistone deacetylase 2Homo sapiens (human)
chromatin remodelingHistone deacetylase 2Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 2Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 2Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by competitive promoter bindingHistone deacetylase 2Homo sapiens (human)
negative regulation of neuron projection developmentHistone deacetylase 2Homo sapiens (human)
dendrite developmentHistone deacetylase 2Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 2Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 2Homo sapiens (human)
response to caffeineHistone deacetylase 2Homo sapiens (human)
heterochromatin formationHistone deacetylase 2Homo sapiens (human)
response to lipopolysaccharideHistone deacetylase 2Homo sapiens (human)
positive regulation of interleukin-1 productionHistone deacetylase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionHistone deacetylase 2Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 2Homo sapiens (human)
positive regulation of collagen biosynthetic processHistone deacetylase 2Homo sapiens (human)
cellular response to heatHistone deacetylase 2Homo sapiens (human)
response to nicotineHistone deacetylase 2Homo sapiens (human)
protein modification processHistone deacetylase 2Homo sapiens (human)
response to cocaineHistone deacetylase 2Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinHistone deacetylase 2Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 2Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 2Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityHistone deacetylase 2Homo sapiens (human)
negative regulation of MHC class II biosynthetic processHistone deacetylase 2Homo sapiens (human)
positive regulation of proteolysisHistone deacetylase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 2Homo sapiens (human)
behavioral response to ethanolHistone deacetylase 2Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 2Homo sapiens (human)
response to hyperoxiaHistone deacetylase 2Homo sapiens (human)
hair follicle placode formationHistone deacetylase 2Homo sapiens (human)
negative regulation of dendritic spine developmentHistone deacetylase 2Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 2Homo sapiens (human)
fungiform papilla formationHistone deacetylase 2Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 2Homo sapiens (human)
cellular response to retinoic acidHistone deacetylase 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusHistone deacetylase 2Homo sapiens (human)
positive regulation of male mating behaviorHistone deacetylase 2Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 2Homo sapiens (human)
cellular response to dopamineHistone deacetylase 2Homo sapiens (human)
response to amyloid-betaHistone deacetylase 2Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 2Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationHistone deacetylase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPolyamine deacetylase HDAC10Homo sapiens (human)
DNA repairPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationPolyamine deacetylase HDAC10Homo sapiens (human)
regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
macroautophagyPolyamine deacetylase HDAC10Homo sapiens (human)
positive regulation of mismatch repairPolyamine deacetylase HDAC10Homo sapiens (human)
homologous recombinationPolyamine deacetylase HDAC10Homo sapiens (human)
negative regulation of DNA-templated transcriptionPolyamine deacetylase HDAC10Homo sapiens (human)
polyamine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
spermidine deacetylationPolyamine deacetylase HDAC10Homo sapiens (human)
epigenetic regulation of gene expressionPolyamine deacetylase HDAC10Homo sapiens (human)
chromatin organizationHistone deacetylase 11 Homo sapiens (human)
oligodendrocyte developmentHistone deacetylase 11 Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 11 Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 8Homo sapiens (human)
chromatin organizationHistone deacetylase 8Homo sapiens (human)
mitotic sister chromatid cohesionHistone deacetylase 8Homo sapiens (human)
negative regulation of protein ubiquitinationHistone deacetylase 8Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 8Homo sapiens (human)
regulation of telomere maintenanceHistone deacetylase 8Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 8Homo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 9Homo sapiens (human)
negative regulation of cytokine productionHistone deacetylase 9Homo sapiens (human)
response to amphetamineHistone deacetylase 9Homo sapiens (human)
inflammatory responseHistone deacetylase 9Homo sapiens (human)
heart developmentHistone deacetylase 9Homo sapiens (human)
neuron differentiationHistone deacetylase 9Homo sapiens (human)
B cell differentiationHistone deacetylase 9Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 9Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 9Homo sapiens (human)
B cell activationHistone deacetylase 9Homo sapiens (human)
cholesterol homeostasisHistone deacetylase 9Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 9Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 9Homo sapiens (human)
regulation of skeletal muscle fiber developmentHistone deacetylase 9Homo sapiens (human)
regulation of striated muscle cell differentiationHistone deacetylase 9Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
inflammatory responseHistone deacetylase 5Homo sapiens (human)
response to xenobiotic stimulusHistone deacetylase 5Homo sapiens (human)
regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 5Homo sapiens (human)
response to activityHistone deacetylase 5Homo sapiens (human)
neuron differentiationHistone deacetylase 5Homo sapiens (human)
B cell differentiationHistone deacetylase 5Homo sapiens (human)
cellular response to insulin stimulusHistone deacetylase 5Homo sapiens (human)
B cell activationHistone deacetylase 5Homo sapiens (human)
response to cocaineHistone deacetylase 5Homo sapiens (human)
regulation of protein bindingHistone deacetylase 5Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 5Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 5Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone deacetylase 5Homo sapiens (human)
cellular response to lipopolysaccharideHistone deacetylase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisHistone deacetylase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor corepressor 2Homo sapiens (human)
lactationNuclear receptor corepressor 2Homo sapiens (human)
response to organonitrogen compoundNuclear receptor corepressor 2Homo sapiens (human)
regulation of cellular ketone metabolic processNuclear receptor corepressor 2Homo sapiens (human)
cerebellum developmentNuclear receptor corepressor 2Homo sapiens (human)
response to estradiolNuclear receptor corepressor 2Homo sapiens (human)
estrous cycleNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNuclear receptor corepressor 2Homo sapiens (human)
negative regulation of miRNA transcriptionNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (64)

Processvia Protein(s)Taxonomy
transcription corepressor bindingHistone deacetylase 3Homo sapiens (human)
chromatin bindingHistone deacetylase 3Homo sapiens (human)
transcription corepressor activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase activityHistone deacetylase 3Homo sapiens (human)
protein bindingHistone deacetylase 3Homo sapiens (human)
enzyme bindingHistone deacetylase 3Homo sapiens (human)
cyclin bindingHistone deacetylase 3Homo sapiens (human)
chromatin DNA bindingHistone deacetylase 3Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 3Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 3Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 3Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 3Homo sapiens (human)
protein decrotonylase activityHistone deacetylase 3Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 3Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 3Homo sapiens (human)
cytokine activityNicotinamide phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
nicotinamide phosphoribosyltransferase activityNicotinamide phosphoribosyltransferaseHomo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 4Homo sapiens (human)
histone bindingHistone deacetylase 4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase activityHistone deacetylase 4Homo sapiens (human)
protein bindingHistone deacetylase 4Homo sapiens (human)
zinc ion bindingHistone deacetylase 4Homo sapiens (human)
SUMO transferase activityHistone deacetylase 4Homo sapiens (human)
potassium ion bindingHistone deacetylase 4Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 4Homo sapiens (human)
identical protein bindingHistone deacetylase 4Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 4Homo sapiens (human)
molecular adaptor activityHistone deacetylase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 4Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
chromatin bindingHistone deacetylase 7Homo sapiens (human)
transcription corepressor activityHistone deacetylase 7Homo sapiens (human)
histone deacetylase activityHistone deacetylase 7Homo sapiens (human)
protein kinase C bindingHistone deacetylase 7Homo sapiens (human)
protein bindingHistone deacetylase 7Homo sapiens (human)
SUMO transferase activityHistone deacetylase 7Homo sapiens (human)
protein kinase bindingHistone deacetylase 7Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 7Homo sapiens (human)
metal ion bindingHistone deacetylase 7Homo sapiens (human)
14-3-3 protein bindingHistone deacetylase 7Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 7Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 2Homo sapiens (human)
chromatin bindingHistone deacetylase 2Homo sapiens (human)
RNA bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase activityHistone deacetylase 2Homo sapiens (human)
protein bindingHistone deacetylase 2Homo sapiens (human)
enzyme bindingHistone deacetylase 2Homo sapiens (human)
heat shock protein bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 2Homo sapiens (human)
histone bindingHistone deacetylase 2Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 2Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 2Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 2Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activityHistone deacetylase 2Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 2Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
protein bindingPolyamine deacetylase HDAC10Homo sapiens (human)
zinc ion bindingPolyamine deacetylase HDAC10Homo sapiens (human)
deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
enzyme bindingPolyamine deacetylase HDAC10Homo sapiens (human)
protein lysine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase bindingPolyamine deacetylase HDAC10Homo sapiens (human)
acetylputrescine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
acetylspermidine deacetylase activityPolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase activityHistone deacetylase 11 Homo sapiens (human)
protein bindingHistone deacetylase 11 Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 11 Homo sapiens (human)
histone deacetylase activityHistone deacetylase 8Homo sapiens (human)
protein bindingHistone deacetylase 8Homo sapiens (human)
Hsp70 protein bindingHistone deacetylase 8Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 8Homo sapiens (human)
metal ion bindingHistone deacetylase 8Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 8Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 8Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 8Homo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein kinase C bindingHistone deacetylase 9Homo sapiens (human)
protein bindingHistone deacetylase 9Homo sapiens (human)
histone H3K14 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H3K9 deacetylase activityHistone deacetylase 9Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone H4K16 deacetylase activityHistone deacetylase 9Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 9Homo sapiens (human)
metal ion bindingHistone deacetylase 9Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 9Homo sapiens (human)
transcription cis-regulatory region bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 5Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 5Homo sapiens (human)
chromatin bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase activityHistone deacetylase 5Homo sapiens (human)
protein kinase C bindingHistone deacetylase 5Homo sapiens (human)
protein bindingHistone deacetylase 5Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 5Homo sapiens (human)
identical protein bindingHistone deacetylase 5Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 5Homo sapiens (human)
metal ion bindingHistone deacetylase 5Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 5Homo sapiens (human)
DNA bindingNuclear receptor corepressor 2Homo sapiens (human)
chromatin bindingNuclear receptor corepressor 2Homo sapiens (human)
transcription corepressor activityNuclear receptor corepressor 2Homo sapiens (human)
Notch bindingNuclear receptor corepressor 2Homo sapiens (human)
protein bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
histone deacetylase bindingNuclear receptor corepressor 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
nucleusHistone deacetylase 3Homo sapiens (human)
nucleoplasmHistone deacetylase 3Homo sapiens (human)
cytoplasmHistone deacetylase 3Homo sapiens (human)
Golgi apparatusHistone deacetylase 3Homo sapiens (human)
cytosolHistone deacetylase 3Homo sapiens (human)
plasma membraneHistone deacetylase 3Homo sapiens (human)
mitotic spindleHistone deacetylase 3Homo sapiens (human)
histone deacetylase complexHistone deacetylase 3Homo sapiens (human)
transcription repressor complexHistone deacetylase 3Homo sapiens (human)
nucleusHistone deacetylase 3Homo sapiens (human)
cytosolNicotinamide phosphoribosyltransferaseHomo sapiens (human)
nuclear speckNicotinamide phosphoribosyltransferaseHomo sapiens (human)
cell junctionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinamide phosphoribosyltransferaseHomo sapiens (human)
nucleusHistone deacetylase 4Homo sapiens (human)
nucleoplasmHistone deacetylase 4Homo sapiens (human)
cytoplasmHistone deacetylase 4Homo sapiens (human)
cytosolHistone deacetylase 4Homo sapiens (human)
nuclear speckHistone deacetylase 4Homo sapiens (human)
histone deacetylase complexHistone deacetylase 4Homo sapiens (human)
chromatinHistone deacetylase 4Homo sapiens (human)
transcription repressor complexHistone deacetylase 4Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 7Homo sapiens (human)
nucleoplasmHistone deacetylase 7Homo sapiens (human)
cytoplasmHistone deacetylase 7Homo sapiens (human)
cytosolHistone deacetylase 7Homo sapiens (human)
chromosome, telomeric regionHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleoplasmHistone deacetylase 2Homo sapiens (human)
cytoplasmHistone deacetylase 2Homo sapiens (human)
NuRD complexHistone deacetylase 2Homo sapiens (human)
Sin3-type complexHistone deacetylase 2Homo sapiens (human)
histone deacetylase complexHistone deacetylase 2Homo sapiens (human)
chromatinHistone deacetylase 2Homo sapiens (human)
protein-containing complexHistone deacetylase 2Homo sapiens (human)
ESC/E(Z) complexHistone deacetylase 2Homo sapiens (human)
nucleusHistone deacetylase 2Homo sapiens (human)
nucleusPolyamine deacetylase HDAC10Homo sapiens (human)
nucleoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytoplasmPolyamine deacetylase HDAC10Homo sapiens (human)
cytosolPolyamine deacetylase HDAC10Homo sapiens (human)
intracellular membrane-bounded organellePolyamine deacetylase HDAC10Homo sapiens (human)
histone deacetylase complexPolyamine deacetylase HDAC10Homo sapiens (human)
nucleusHistone deacetylase 11 Homo sapiens (human)
plasma membraneHistone deacetylase 11 Homo sapiens (human)
histone deacetylase complexHistone deacetylase 11 Homo sapiens (human)
nuclear chromosomeHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleoplasmHistone deacetylase 8Homo sapiens (human)
cytoplasmHistone deacetylase 8Homo sapiens (human)
histone deacetylase complexHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 8Homo sapiens (human)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
nucleusHistone deacetylase 9Homo sapiens (human)
nucleoplasmHistone deacetylase 9Homo sapiens (human)
cytoplasmHistone deacetylase 9Homo sapiens (human)
histone deacetylase complexHistone deacetylase 9Homo sapiens (human)
transcription regulator complexHistone deacetylase 9Homo sapiens (human)
histone methyltransferase complexHistone deacetylase 9Homo sapiens (human)
nucleusHistone deacetylase 5Homo sapiens (human)
nucleoplasmHistone deacetylase 5Homo sapiens (human)
cytoplasmHistone deacetylase 5Homo sapiens (human)
Golgi apparatusHistone deacetylase 5Homo sapiens (human)
cytosolHistone deacetylase 5Homo sapiens (human)
nuclear speckHistone deacetylase 5Homo sapiens (human)
histone deacetylase complexHistone deacetylase 5Homo sapiens (human)
nucleusNuclear receptor corepressor 2Homo sapiens (human)
nucleoplasmNuclear receptor corepressor 2Homo sapiens (human)
membraneNuclear receptor corepressor 2Homo sapiens (human)
nuclear matrixNuclear receptor corepressor 2Homo sapiens (human)
nuclear bodyNuclear receptor corepressor 2Homo sapiens (human)
chromatinNuclear receptor corepressor 2Homo sapiens (human)
transcription repressor complexNuclear receptor corepressor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (138)

Assay IDTitleYearJournalArticle
AID1541826Inhibition of NAMPT in human HL60 cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NMN by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1541817Antiproliferative activity against human HL60 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1541828Inhibition of NAMPT in human HEL cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NMN by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1899790Metabolic stability in dog liver microsomes assessed as intrinsic clearance measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899795Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589335Inhibition of HDAC1 (unknown origin) using Fluor de Lys substrate at 50 uM by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1899797Antiproliferative activity against human HCT-116 cells assessed as remaining cell activity at 2 uM incubated for 72 hrs by luminescence assay relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1594032Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1825153Metabolic stability in human plasma assessed as parent compound remaining at 100 uM measured after 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1594030Inhibition of recombinant human HDAC6 at 50 uM using Fluor-de-Lys as substrate measured after 10 mins by fluorescence assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1541809Inhibition of recombinant human C-terminal His-tagged HDAC2 expressed in baculovirus expression system using Ac-peptide as substrate incubated for 60 mins by fluorometric method2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1825146Metabolic stability in monkey liver microsomes assessed as intrinsic clearance incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1541822Inhibition of NAMPT in human HCT116 cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NMN by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1740040Inhibition of HDAC1 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1541811Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1541825Inhibition of NAMPT in human HL60 cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NA by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1899835AUC (0 to infinity) in ICR mouse at 2 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899800Antiproliferative activity against human A549 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1740117Inhibition of HDAC9 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1594028Inhibition of human ARAF using human His6-tagged MEK1 (K97R) as substrate preincubated for 20 mins followed by [33P-gamma]ATP addition and measured after 2 hrs by filter-binding assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1884295Induction of apoptosis in human HCT-116 cells assessed as dead cells at 0.5 uM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry (Rvb = 4.62 %)2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1825155Metabolic stability in dog plasma assessed as parent compound remaining at 100 uM measured after 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1899809Antiproliferative activity against human TMD8 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1884292Induction of apoptosis in human HCT-116 cells assessed as viable cells at 0.5 uM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry (Rvb = 93.64%)2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1740114Inhibition of HDAC6 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1899836AUC (0 to infinity) in ICR mouse at 25 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1825143Metabolic stability in dog liver microsomes assessed as half life incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1589347Antiproliferative activity against human HL60 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1899834Half life in ICR mouse at 25 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589419Metabolic stability in dog liver microsomes assessed as half life at 1 uM preincubated for 10 mins followed by NADPH addition measured upto 60 mins by LC-MS/MS analysis2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1899822Metabolic stability in rat liver microsomes assessed as intrinsic clearance measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899821Metabolic stability in monkey liver microsomes assessed as intrinsic clearance measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589346Inhibition of HDAC11 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1899801Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1884268Inhibition of human HDAC1 using RHKKAc fluorogenic peptide as substrate preincubated for 10 mins followed by substrate addition by fluorescence based analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1589349Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1594055Cytotoxicity against human CCRF-CEM cells by MTT assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
A new lateral root growth inhibitor from the sponge-derived fungus Aspergillus sp. LS45.
AID1594035Antiproliferative activity against human MDA-MB-468 cells measured after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1541816Antiproliferative activity against human K562 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1740042Inhibition of HDAC3 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1589421Metabolic stability in rat liver microsomes assessed as half life at 1 uM preincubated for 10 mins followed by NADPH addition measured upto 60 mins by LC-MS/MS analysis2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1899806Antiproliferative activity against human NCI-H441 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1594025Inhibition of recombinant human N-terminal GST-tagged BRAF V600E mutant catalytic domain (416 to 766 residues) expressed in baculovirus expression system using human His6-tagged MEK1 (K97R) as substrate preincubated for 20 mins followed by [33P-gamma]ATP 2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1884270Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1884293Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 0.5 uM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry (Rvb = 0.93 %)2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1899817Metabolic stability in mouse liver microsomes assessed as half life measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1594034Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1899807Antiproliferative activity against human 22Rv1 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589340Inhibition of HDAC4 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1877808Cytotoxicity against human K562 cells measured after 72 hrs by MTT assay
AID1899816Antiproliferative activity against human RS4-11 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899789Inhibition of HDAC1 (unknown origin) using RHKK(Ac)AMC fluorogenic peptide as substrate preincubated for 10 mins followed by substrate addition for 1 hr in presence of ATP by fluoroscence based assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899837MRT in ICR mouse at 25 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1379287Inhibition of recombinant human full length HDAC1 expressed in baculovirus infected Sf9 insect cells using biotinylated lysine 9 acetylated histone H3 (1 to 21 residues) as substrate incubated for 5 mins followed by substrate addition measured after 60 mi2017ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID1825141Metabolic stability in human liver microsomes assessed as half life incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1899814Antiproliferative activity against human MOLT-4 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1541812Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1884269Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1899803Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899802Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589417Metabolic stability in human liver microsomes assessed as internal clearance at 1 uM preincubated for 10 mins followed by NADPH addition measured upto 60 mins by LC-MS/MS analysis2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1594033Antiproliferative activity against human MV4-11 cells measured after 48 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1379288Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay2017ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID1541827Inhibition of NAMPT in human HEL cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NA by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1825148Metabolic stability in rat liver microsomes assessed as intrinsic clearance incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1740131Inhibition of HDAC4 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1541810Inhibition of human recombinant C-terminal His-tagged HDAC3/NCOR2 (395 to 489 residus) using Ac-peptide as substrate incubated for 60 mins by fluorometric method2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1899815Antiproliferative activity against human HuT78 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1884294Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 0.5 uM incubated for 24 hrs by AnnexinV-FITC/PI staining based flow cytometry (Rvb = 0.82 %)2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1877810Cytotoxicity against human U-937 cells measured after 72 hrs by MTT assay
AID1899808Antiproliferative activity against human 786-O cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899812Antiproliferative activity against human SUDHL2 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1594029Inhibition of human CRAF using human His6-tagged MEK1 (K97R) as substrate preincubated for 20 mins followed by [33P-gamma]ATP addition and measured after 2 hrs by filter-binding assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1589338Inhibition of HDAC3 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1740041Inhibition of HDAC2 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1825151Metabolic stability in dog plasma assessed as half life at 100 uM measured upto 120 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1594031Inhibition of recombinant full-length human C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 insect cells at 50 uM using Fluor-de-Lys as substrate measured after 10 mins by fluorescence assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1899805Antiproliferative activity against human COLO-678 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1825154Metabolic stability in monkey plasma assessed as parent compound remaining at 100 uM measured after 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1884271Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by luminescence based analysis2022European journal of medicinal chemistry, Aug-05, Volume: 238Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.
AID1589418Metabolic stability in human liver microsomes assessed as half life at 1 uM preincubated for 10 mins followed by NADPH addition measured upto 60 mins by LC-MS/MS analysis2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1825076Binding affinity to SNAI1 (unknown origin) assessed as dissociation constant2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1899810Antiproliferative activity against human DOHH-2 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589348Antiproliferative activity against human K562 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1541808Inhibition of recombinant full length human HDAC1 (1 to 482 residues) expressed in baculovirus expression system using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorometric me2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1739999Inhibition of HDAC10 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1899820Metabolic stability in rat liver microsomes assessed as half life measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589343Inhibition of HDAC9 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1541821Inhibition of NAMPT in human HCT116 cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NA by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1541815Antiproliferative activity against human HCT116 cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1589339Inhibition of HDAC8 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1899798Antiproliferative activity against human A549 cells assessed as remaining cell activity at 2 uM incubated for 72 hrs by luminescence assay relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1594056Cytotoxicity against human K562 cells by MTT assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
A new lateral root growth inhibitor from the sponge-derived fungus Aspergillus sp. LS45.
AID1899819Metabolic stability in dog liver microsomes assessed as half life measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1541824Inhibition of NAMPT in human K562 cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NMN by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1379286Inhibition of recombinant human His-tagged c-Met cytoplasmic domain (956 to 1390 residues) expressed in baculovirus expression system using poly (Glu,Tyr)4:1 as substrate after 60 mins by spectrophotometric analysis2017ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID1589341Inhibition of HDAC5 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1541820Inhibition of NAMPT in human HCT116 cells assessed as decrease in cellular NAD+ level after 24 hrs by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1825152Metabolic stability in rat plasma assessed as half life at 100 uM measured upto 120 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1825142Metabolic stability in monkey liver microsomes assessed as half life incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1589350Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 72 hrs using alamar blue based fluorescence method2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1899804Antiproliferative activity against human HT-29 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1379289Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay2017ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.
AID1589344Inhibition of HDAC6 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1541823Inhibition of NAMPT in human K562 cells assessed as decrease in cellular NAD+ level after 24 hrs in presence of NA by MTT assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1740113Inhibition of HDAC5 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1899838Oral bioavailability in ICR mouse at 25 mg/kg measured upto 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589420Metabolic stability in dog liver microsomes assessed as internal clearance at 1 uM preincubated for 10 mins followed by NADPH addition measured upto 60 mins by LC-MS/MS analysis2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1594026Inhibition of recombinant full-length human C-terminal FLAG/His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using Fluor-de-Lys as substrate measured after 10 mins by fluorescence assay2019Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
AID1589345Inhibition of HDAC10 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1541807Inhibition of human NAMPT using NAM and PRPP as substrates incubated for 90 mins in presence of NMNAT by fluorometric method2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1589342Inhibition of HDAC7 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1589337Inhibition of HDAC2 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1825074Antiproliferative activity against human HCT-116 cells assessed as cell viability at 1 uM incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1541813Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1899833Cmax in ICR mouse at 25 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1589422Metabolic stability in rat liver microsomes assessed as internal clearance at 1 uM preincubated for 10 mins followed by NADPH addition measured upto 60 mins by LC-MS/MS analysis2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1589336Inhibition of HDAC1 (unknown origin) using Fluor de Lys substrate by fluorescence assay relative to control2019European journal of medicinal chemistry, Apr-15, Volume: 168Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
AID1877809Cytotoxicity against human CCRF-CEM cells measured after 72 hrs by MTT assay
AID1825156Metabolic stability in rat plasma assessed as parent compound remaining at 100 uM measured after 2 hrs by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1899818Metabolic stability in monkey liver microsomes assessed as half life measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1825073Inhibition of HDAC1 (unknown origin) using p53 (379 to 382 residues) (RHKK(Ac-AMC) as fluorogenic substrate incubated for 1 hrs by fluorescence based assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1825144Metabolic stability in rat liver microsomes assessed as half life incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1740115Inhibition of HDAC7 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1825145Metabolic stability in human liver microsomes assessed as intrinsic clearance incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1899811Antiproliferative activity against human CCRF-CEM cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1825147Metabolic stability in dog liver microsomes assessed as intrinsic clearance incubated for 10 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of dual inhibitors targeting snail and histone deacetylase for the treatment of solid tumour cancer.
AID1899799Antiproliferative activity against human MDA-MB-231 cells assessed as remaining cell activity at 2 uM incubated for 72 hrs by luminescence assay relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1541819Binding affinity to NAMPT in human HCt116 cells assessed as increase in stability of cellular NAMPT at 10 uM preincubated for 2 hrs followed by heating at 49 to 70 degC for 3 mins by Western blot-based CESTA2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1899813Antiproliferative activity against human REC1 cells incubated for 72 hrs by luminescence assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1915571Inhibition of HDAC (unknown origin)2021European journal of medicinal chemistry, Jan-01, Volume: 209Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1541818Antiproliferative activity against human HEL cells NAMPT deficient assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
AID1899793Metabolic stability in human liver microsomes assessed as half life measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1740116Inhibition of HDAC8 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1899796Antiproliferative activity against human TMD8 cells assessed as remaining cell activity at 2 uM incubated for 72 hrs by luminescence assay relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1899794Metabolic stability in human liver microsomes assessed as intrinsic clearance measured for 75 to 130 mins by LC-MS/MS analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics.
AID1740134Inhibition of HDAC11 (unknown origin)2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1541814Antiproliferative activity against human HEL cells assessed as reduction in cell viability after 72 hrs by CCK8 assay2020ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (35.29)24.3611
2020's11 (64.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.95 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index57.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.88%)5.53%
Reviews2 (11.76%)6.00%
Case Studies1 (5.88%)4.05%
Observational0 (0.00%)0.25%
Other13 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4,5,6,7-tetrabromo-2-azabenzimidazole
4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor		3.4110
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		2.2110aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
entinostat
[no description available]		4.2920benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
imatinib
[no description available]		3.4110aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		4.7440dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
prednisone
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.		4.551111-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		3.4110alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		2.6320
bendamustine
[no description available]		3.4110benzimidazoles
n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide
[no description available]		3.4110
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		3.41109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
erlotinib
[no description available]		3.4110aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
lapatinib
[no description available]		3.4110furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sorafenib
[no description available]		3.7620(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		3.7620antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		3.41101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
zd 6474
CH 331: structure in first source		3.4110aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor
cholecalciferol
Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.		3.4110D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
casein kinase ii
Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.		3.4110
pd 404182
[no description available]		3.3510
fk 866
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide: inhibits nicotinamide phosphoribosyltransferase; structure in first source		2.2510benzamides;
N-acylpiperidine
givinostat
[no description available]		3.3510carbamate ester
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		3.3510aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
quisinostat
[no description available]		3.3510indoles
abexinostat
abexinostat: structure in first source		3.3510benzofurans
gdc 0941
pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.		3.4110indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
pci 34051
PCI 34051: an HDAC8 inhibitor		3.3510indolecarboxamide
cudc 101
7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide: a histone deacetylase inhibitor; structure in first source		3.4110
abemaciclib
[no description available]		3.4110
tubastatin a
[no description available]		3.3510hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor
acy-1215
ricolinostat: an HDAC6 inhibitor; structure in first source		4.2920pyrimidinecarboxylic acid
cudc-907
[no description available]		3.3510
tasquinimod
tasquinimod: a lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer; structure in first source		3.3510
osimertinib
osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.		3.4110acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
onc201
TIC10 compound: a TRAIL-dependent antitumor agent; structure in first source		2.4110
ConditionIndicatedRelationship StrengthStudiesTrials
Germinoblastoma
[description not available]		03.1710
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		15.1710
Diffuse Large B-Cell Lymphoma
[description not available]		05.0221
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		17.0221
Colorectal Cancer
[description not available]		02.4110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		14.4110
Cancer of Colon
[description not available]		02.3110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.3110
Recrudescence
[description not available]		02.4110
Brill-Symmers Disease
[description not available]		02.4110
ATLL
[description not available]		02.6120
Lymphoma, Follicular
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.		14.4110
Leukemia-Lymphoma, Adult T-Cell
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.		02.6120
Benign Neoplasms
[description not available]		02.4110
Lymphoma, T Cell, Peripheral
[description not available]		02.4110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		14.4110
Lymphoma, T-Cell, Peripheral
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.		14.8220
Acute Myelogenous Leukemia
[description not available]		02.1510
Local Neoplasm Recurrence
[description not available]		02.1510
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		14.1510